Pia Loren
Overview
Explore the profile of Pia Loren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
97
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Herrera-Bravo J, Belen L, Reyes M, Silva V, Fuentealba S, Paz C, et al.
Naunyn Schmiedebergs Arch Pharmacol
. 2024 Jun;
397(11):8259-8284.
PMID: 38847831
Cancer remains a global health challenge, prompting a search for effective treatments with fewer side effects. Thymol, a natural monoterpenoid phenol derived primarily from thyme (Thymus vulgaris) and other plants...
2.
Rodriguez N, Loren P, Paez I, Martinez C, Chaparro A, Salazar L
Int J Mol Sci
. 2024 Feb;
25(4).
PMID: 38396672
Cardiovascular diseases are the leading cause of death worldwide, and arterial hypertension is a recognized cardiovascular risk factor that is responsible for high morbidity and mortality. Arterial hypertension is the...
3.
miR-6805-5p as a biomarker of cisplatin-induced nephrotoxicity in patients with head and neck cancer
Torso N, Quintanilha J, Cursino M, Pincinato E, Loren P, Salazar L, et al.
Front Pharmacol
. 2023 Dec;
14:1275238.
PMID: 38089043
The standard treatment for head and neck squamous cell carcinoma (HNSCC) is cisplatin chemoradiotherapy. One of the main treatment adverse reactions is nephrotoxicity, for which there is currently no adequate...
4.
Letelier P, Saldias R, Loren P, Riquelme I, Guzman N
Int J Mol Sci
. 2023 Dec;
24(23).
PMID: 38069307
Exposure to atmospheric air pollution containing volatile organic compounds such as polycyclic aromatic hydrocarbons (PAHs) has been shown to be a risk factor in the induction of lung inflammation and...
5.
Paez I, Prado Y, Loren P, Ubilla C, Rodriguez N, Salazar L
Biomedicines
. 2023 Mar;
11(3).
PMID: 36979720
Statins are currently the treatment of choice for hypercholesterolemia. However, wide interindividual variability has been observed in the response to treatment. Recent studies have reported the role of lncRNAs in...
6.
Lugones Y, Loren P, Salazar L
Biomolecules
. 2022 Oct;
12(10).
PMID: 36291573
Cisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor cells can acquire resistance to the damage caused by cisplatin, generating genetic and epigenetic changes that...
7.
Loren P, Lugones Y, Saavedra N, Saavedra K, Paez I, Rodriguez N, et al.
Biomolecules
. 2022 Sep;
12(9).
PMID: 36139046
Cisplatin (-diamminedichloroplatinum (II), DDP) is an antineoplastic agent widely used in the treatment of solid tumors because of its extensive cytotoxic activity. However, the main limiting side effect of DDP...
8.
Loren P, Saavedra N, Saavedra K, Torso N, Visacri M, Moriel P, et al.
Front Pharmacol
. 2022 Apr;
13:831099.
PMID: 35444536
Cisplatin (DDP) is a well-known anticancer drug used for the treatment of numerous human cancers in solid organs, including bladder, breast, cervical, head and neck squamous cell, ovarian, among others....
9.
Torso N, Pereira J, Visacri M, Vasconcelos P, Loren P, Saavedra K, et al.
Int J Mol Sci
. 2021 Dec;
22(23).
PMID: 34884570
The purpose of this systematic review was to map out and summarize scientific evidence on dysregulated microRNAs (miRNAs) that can be possible biomarkers or therapeutic targets for cisplatin nephrotoxicity and...
10.
Visacri M, Nicoletti A, Pincinato E, Loren P, Saavedra N, Saavedra K, et al.
Biomark Med
. 2021 Nov;
15(18):1785-1795.
PMID: 34784802
miRNAs are potential biomarkers of several diseases. This review aimed to identify the miRNAs that could serve as biomarkers of COVID-19. A literature search of nine databases was carried out...